4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
bdbiosciences
主营：主营：医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > peptide > BD Biosciences/抗人CD8 FITC/CD38 PE/CD3 PerCP/HLA-DR APC/20µL/340572
商品详细BD Biosciences/抗人CD8 FITC/CD38 PE/CD3 PerCP/HLA-DR APC/20µL/340572
BD Biosciences/抗人CD8 FITC/CD38 PE/CD3 PerCP/HLA-DR APC/20µL/340572
BD Biosciences/抗人CD8 FITC/CD38 PE/CD3 PerCP/HLA-DR APC/20µL/340572
商品编号： 340572
品牌： bdbiosciences
市场价： ¥28035.00
美元价： 16020.00
产地： 美国(厂家直采)
公司：
产品分类： 多肽合成
公司分类： peptide
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
Product DetailsRecommended AssayReferences

Description

CD8, clone SK1, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with human peripheral blood T lymphocytes.

CD38, clone HB7, is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with spleen cells from BALB/c mice immunized with the BJAB cell line.

CD3, clone SK7, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with human thymocytes.

Anti–HLA-DR, clone L243, is derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells from BALB/c mice immunized with the human lymphoblastoid B-cell line RPMI 8866.

CD8 recognizes an antigen expressed on the 32-kDalton (kDa) α subunit of a disulfide-linked bimolecular complex. The cytoplasmic domain of the α subunit of the CD8 antigen is associated with the protein tyrosine kinase p56lck. The CD8 molecule interacts with class I major histocompatibility complex (MHC) molecules resulting in increased adhesion between the CD8+T lymphocytes and the target cells. Binding of the CD8 molecule to class I MHC molecules enhances the activation of resting T lymphocytes.

CD38 recognizes an integral membrane glycoprotein, Mr 45 kDa, with a protein core of 35 kDa.

CD3 recognizes the epsilon chain of the CD3 antigen/T-cell antigen receptor (TCR) complex. This complex is composed of at least six proteins that range in molecular weight from 20 to 30 kDa. The antigen recognized by the CD3 antibody is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kDa).

Anti–HLA-DR recognizes a human class II MHC antigen. The antigen is a transmembrane glycoprotein composed of α and β subunits that have molecular weights of 36 and 27 kDa, respectively. Anti–HLA-DR reacts with a nonpolymorphic HLA-DR epitope and does not cross-react with HLA-DQ or HLA-DP molecules.

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
HLA-DRL243APCIgG2a, κ0
CD8SK1FITCIgG1, κ925
CD38HB7 (also known as HB-7)PEIgG1, κ952
CD3SK7 (also known as Leu-4)PerCPIgG1, κ916
Resources & Tools
SpectrumViewerDownload TDSDownload MSDS
Preparation and Storage

The MultiTEST reagent is supplied as a combination of CD8 FITC, CD38 PE, CD3 PerCP, and Anti–HLA-DR APC in 1.0 mL of PBS containing bovine serum albumin, and 0.1% sodium azide. Vials should be stored at 2° to 8°C. Conjugated forms should not be frozen and should be protected from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

  1. Anderson P, Blue M-L, Morimoto C, Schlossman SF. Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes. J Immunol. 1987;139:678-682.

  2. Benito J, Zabay J, Gil J, Bermejo M, Escudero A, Sánchez E, Fernández-Cruz E. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: Changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD35 antigens. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:128-135.

  3. Bishop GA, Hall BM, Duggin GG, Horvath JS, Sheil AGR, Tiller DJ. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. Kidney Internat. 1986;29:708- 717.

  4. Bogner J, Matuschke B, Hienrich B, Schreiber M, Nerl C, Goebel F. Expansion of activated T lymphocytes (CD3+HLA-DR+) detectable in early stages of HIV-1 infection. Klin Wochenschr. 1990;68:393-396.

  5. Brenner M, Groh V, Porcelli F, Hochstenbach H, et al. Structure and distribution of the human gd T-cell receptor. In: Knapp W, Dörken B, Gilks W, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:1049-1053.

  6. Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics. 1984;19:179-194.

  7. Carney W, IacovielloV, Hirsh M. Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol. 1983;130:390-393.

  8. Clevers H. Alarcón B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual Rev Immunol. 1988;(6):629.

  9. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, et al. B-cell antigens: CD38. In: Knapp W, Dörken B, Gilks W, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York: Oxford University Press; 1989:86.

  10. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLADP, DQ, and DR to immunoglobulin expression. J Immunol. 1986;137:490-497.

  11. Eichmann K, Johnson J, Falk I, Emmrich F. Effective activation of resting mouse T lymphocytes by cross-linking submitogenic concentrations of the T-cell antigen receptor with either Lyt-2 or L3T4. Eur J Immunol. 1987;17:643-650.

  12. Engleman EG, Benike CJ, Evans RL. Circulating antigen-specific suppressor T cells in a healthy woman: mechanism of action and isolation with a monoclonal antibody. Clin Res. 1981;29:365A.

  13. Engleman EG, Benike CJ, Glickman E, Evans RL. Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. J Exp Med. 1981;153:193-198.

  14. Engleman EG, Warnke R, Fox RI, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci USA. 1981;78:791.

  15. Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to the TH2 antigen. Proc Natl Acad Sci USA. 1981;78:544-548.

  16. Gallagher P, Fazekas de St. Groth B, Miller J. CD4 and CD8 molecules can physically associate with the same T-cell receptor. Proc Natl Acad Sci USA. 1989;86:10044-10048.

  17. Garson JA, Beverly PCL, Coakham HB, Harper EJ. Monoclonal antibodies against human T lymphocytes label Purkinje neurons of many species. Nature. 1982;298:375.

  18. Giorgi J, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol. 1989;52:10-18.

  19. Giorgi J, Hultin L. Lymphocyte subset alterations and immunophenotyping by flow cytometry in HIV disease. Clin Immunol Newslett. 1990;10:55-62.

  20. Giorgi JV, Ho H-N, Hirji K, et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis. 1994;170:775-781.

  21. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1993;6:904-912.

  22. Haynes B. β2-interferon/B Leukocyte Typing II: Human T Lymphocytes. 1986:3-30.

  23. Ho HN, Hultin LE, Mitsuyasu RT, et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol. 1993;150:3070-3079.

  24. Kan E, Wang C, Wang L, Evans R. Noncovalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with Anti-Leu-4 antibody. J Immunol. 1983;131:536-539.

  25. Kestens L, Vanham G, Gigase P, et al. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS. 1992;6:793-797.

  26. Knowles R. Immunochemical analysis of the T cell-specific antigens. In: Reinherz E, Haynes B, Nadler L, Bernstein I, eds. Leukocyte Typing II: Human T Lymphocytes. 1986:259-288.

  27. Kotzin BL, Benike CJ, Engleman EG. Induction of immunoglobulin-secreting cells in the allogeneic mixed leukocyte reaction: regulation by helper and suppressor lymphocyte subsets in man. J Immunol. 1981;127:931-935.

  28. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol. 1980;125:293-299.

  29. Landay A, Ohlsson-Wilhelm B, Giorgi J. Application of flow cytometry to the study of HIV infection. AIDS. 1990;4:479-497.

  30. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol. 1986;137:2501-2507.

  31. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983;131:1789-1796.

  32. Ledbetter JA, Frankel AE, Herzenberg LA, Herzenberg LA. Human Leu T-cell differentiation antigens: Quantitative expression on normal lymphoid cells and cell lines. In Hämmerling G, Hämmerling U, Kearney J, eds. Monoclonal Antibodies and T Cell Hybridomas, Perspectives and Technical Advances. New York, NY: Elsevier/North Holland; 1981:16-22.

  33. Legendre C, Schiffrin A, Weitzner G, Colle E, Guttman R. Two-color flow cytometry analysis of activated T-lymphocyte subsets in type 1 diabetes mellitus. Diabetes. 1988;37:792-795.

  34. Lenkei R, Bratt G, Holmberg V, Muirhead K, Sandström E. Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls. Cytometry. 1998;33(2):115-122.

  35. Levacher M, Tallet S, Dazza M, Dournon E, Rouveix B, Pocidalo J. T activation marker evaluation in ARC patients treated with AZT: Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol. 1990;81:177-182.

  36. Linker-Israeli M, Gray J, Quismorio F, Horowitz D. Characterization of lymphocytes that suppress IL-2 production in systemic lypus erythematosus. Clin Exp Immunol. 1988;73:236-241.

  37. Lum L. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369-380.

  38. Moebius U. Cluster report: CD8. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:342-343.

  39. Nicholson J, Jones B. Immunophenotyping by flow cytometry: its use in HIV infection. Labmedica. 1989;6:21-26.

  40. Pantaleo G, De Maria A, Koenig S, et al. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodefieciency virus-specific cytotoxicity. Proc Natl Acad Sci USA. 1990;87:4818-4822.

  41. Pantaleo G, Koenig S, Baseler M, Lane HC, Fauci AS. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol. 1990;144:1696-1704.

  42. Pezzutto A, Behm F, Callard R, et al. Flow cytometry analysis of the B-cell blind panel: Joint Report. In: Knapp W, Dörken B, Gilks W, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:165-174.

  43. Pitzalis C, Kingsley G, Lanchbury J, Murphy J, Panayi G. Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: Evidence for "frustrated" activation. J Rheumatol. 1987;14:662-666.

  44. Prince H, Arens L, Kleinman S. CD4 and CD8 subsets defined by dual-color cytofluorometry which distinguish symptomatic from asymptomatic blood donors seropositive for human immunodeficiency virus. Diag Clin Immunol 1987;5:188-193.

  45. Reichert T, DeBruyère M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopath. 1991;60:190-208.

  46. Reinherz E, Kung P, Goldstein G, Levey R, et al. Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA. 1980;77:1588-1592.

  47. Robbins PA, Evans EL, Ding AH, Warner NL, Brodsky FM. Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Human Immunol. 1987;18:301-313.

  48. Rudd C, Burgess K, Barber E, Schlossman S. Monoclonal antibodies to the CD4 and CD8 antigens precipitate variable amounts of CD4/CD8-associated p56lck activity. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:326-327.

  49. Salazar-Gonzalez J, Moody D, Giorgi J, Martinez-Maza O, et al. Reduced ecto-5"-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: Evidence of CD8 cell immaturity. J Immunol. 1985;135:1778-1785.

  50. Stites D, Casavant C, McHugh T, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol. 1986;38:161-177.

  51. Tedder TF, Clement L, Cooper M. Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. Tissue Antigens. 1984;24:140-149.

  52. Tedder TF, Crain M, Kubagawa H, Clement L, et al. Evaluation of lymphocyte differentiation in primary and secondary immunodeficiency diseases. J Immunol. 1985;135:1786-1791.

  53. Terstappen L, Huang S, Picker L. Flow cytometric assessment of human T cell differentiation in thymus and bone marrow. Blood. 1992;79:666-677.

  54. Terstappen L, Huang S, Safford M, Lansdorp P, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood. 1991;77:1218-1227.

  55. Terstappen LWMM, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol. 1990;48:138-148.

  56. Terstappen LWMM, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leuk Biol. 1990;48:138-148.

  57. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802-3807.

  58. van Dongen J, Krissansen G, Wolvers-Tettero I, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988;71:603-612.

  59. van Es A, Baldwin WM, Oljans PJ, Tanke HJ, Ploem JS, van Es LA. Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation. 1984;37:65-69.

  60. Vanham G, Kestens L, Gigase P, et al. Evidence for circulating activated cytotoxic T cells in HIVinfected subjects before the onset of opportunistic infections. Clin Exp Immunol. 1990;82:3-9.

  61. Vigano A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. The Lancet. 1998;352:1906-1906.

  62. Warnke R, Levy R. Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem. 1980;28:771-776.

  63. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Eng J Med. 1980;303:293-300.

  64. Wood GS, Warner NL, Warnke RA. Anti–Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983;131:212-216.

  65. Zipf TF, Fox RI, Dilley J, Levy R. Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies. Cancer Res. 1981;41:4786-4789.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构，生命科学研究所，临床实验室，工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
公司介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包
品牌分类
HIV Reagent Kits Stem Cell Enumeration BD Multicheck™ Control Other Species Cell Separation Reagents BD Facsunt™ 控制套件 Single-Color Antibodies BD™ Stem Cell Control Kit Sample Multiplexing Reagents 纯化抗体
显示分类
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
快速导航：
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏  0512-67156496（苏州）
版权信息：
©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国
网站备案：
友情链接：
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息